Annexon (NASDAQ:ANNX) Issues Earnings Results, Misses Expectations By $0.05 EPS

Annexon (NASDAQ:ANNX) posted its earnings results on Monday. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05), Zacks reports.

Annexon Stock Performance

ANNX stock opened at $2.64 on Monday. Annexon has a one year low of $2.42 and a one year high of $8.40. The stock has a market capitalization of $281.41 million, a P/E ratio of -2.51 and a beta of 1.07. The company has a 50 day moving average price of $4.01 and a two-hundred day moving average price of $5.45.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research report on Friday, November 15th. HC Wainwright reiterated a “buy” rating and set a $30.00 target price on shares of Annexon in a report on Tuesday, December 17th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Annexon in a research report on Friday, November 15th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Annexon has an average rating of “Buy” and a consensus price target of $15.80.

Annexon Company Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.